Distinct Microbiome-Neuroimmune Signatures Correlate With Functional Abdominal Pain in Children With Autism Spectrum Disorder

Ruth Ann Luna, Numan Oezguen, Miriam Balderas, Alamelu Venkatachalam, Jessica K Runge, James Versalovic, Jeremy Veenstra-VanderWeele, George M Anderson, Tor Savidge, Kent C Williams, Ruth Ann Luna, Numan Oezguen, Miriam Balderas, Alamelu Venkatachalam, Jessica K Runge, James Versalovic, Jeremy Veenstra-VanderWeele, George M Anderson, Tor Savidge, Kent C Williams

Abstract

Background & aims: Emerging data on the gut microbiome in autism spectrum disorder (ASD) suggest that altered host-microbe interactions may contribute to disease symptoms. Although gut microbial communities in children with ASD are reported to differ from individuals with neurotypical development, it is not known whether these bacteria induce pathogenic neuroimmune signals.

Methods: Because commensal clostridia interactions with the intestinal mucosa can regulate disease-associated cytokine and serotonergic pathways in animal models, we evaluated whether microbiome-neuroimmune profiles (from rectal biopsy specimens and blood) differed in ASD children with functional gastrointestinal disorders (ASD-FGID, n = 14) compared with neurotypical (NT) children with FGID (NT-FGID, n = 15) and without abdominal pain (NT, n = 6). Microbial 16S ribosomal DNA community signatures, cytokines, and serotonergic metabolites were quantified and correlated with gastrointestinal symptoms.

Results: A significant increase in several mucosa-associated Clostridiales was observed in ASD-FGID, whereas marked decreases in Dorea and Blautia, as well as Sutterella, were evident. Stratification by abdominal pain showed multiple organisms in ASD-FGID that correlated significantly with cytokines (interleukin [IL]6, IL1, IL17A, and interferon-γ). Group comparisons showed that IL6 and tryptophan release by mucosal biopsy specimens was highest in ASD children with abdominal pain, whereas serotonergic metabolites generally were increased in children with FGIDs. Furthermore, proinflammatory cytokines correlated significantly with several Clostridiales previously reported to associate with ASD, as did tryptophan and serotonin.

Conclusions: Our findings identify distinctive mucosal microbial signatures in ASD children with FGID that correlate with cytokine and tryptophan homeostasis. Future studies are needed to establish whether these disease-associated Clostridiales species confer early pathogenic signals in children with ASD and FGID.

Keywords: 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; ASD, autism spectrum disorder; FGID, functional gastrointestinal disorder; GI, gastrointestinal; GM-CSF, granulocyte-macrophage colony-stimulating factor; GROα, growth-related oncogene alpha; Gastrointestinal Disorders; IBS, irritable bowel syndrome; IFN, interferon; IL, interleukin; IP, interferon gamma-induced protein; MCP-1, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; Microbiome; Microbiome–Gut–Brain Axis; Mucosa; NT, neurotypical; OTU, operational taxonomic unit; QPGS-RIII, Questionnaire on Pediatric Gastrointestinal Symptoms-Rome III; Serotonin; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Separate clusters for the ASD-FGID (blue squares), NT-FGID (green triangles), and NT (orange circles) groups are evident via principal component analysis.
Figure 2
Figure 2
Microbiome profiles per group (ASD-FGID, NT-FGID, and NT) show subtle differences in overall composition at the order level (left). Greater differentiation between the groups was observed when comparisons were made at the OTU level. Right: Clostridiales OTUs that were further identified to the species level. The separation of the ASD-FGID group from the NT-FGID and NT groups was highly driven by both increases and decreases in specific Clostridiales.
Figure 3
Figure 3
Differences in OTUs related to specific bacteria associated with ASD were identified in the mucosal microbial community. Overall, an increase in Clostridiales (C lituseburense, P = .002; L bolteae, P = .017; L hathewayi, P = .030; C aldenense, P = .038; and F plautii, P = .038) was seen in the ASD-FGID group compared with the NT-FGID and NT groups. A decrease in relative abundance in the ASD-FGID group was seen for D formicigenerans (P =.006), B luti (P = .020), and Sutterella species (P = .025). Plots depict the maximum and minimum (whiskers), upper and lower quartile limits (box), and median (horizontal line).
Figure 4
Figure 4
Bacteria associated with pain in ASD-FGID were identified. When comparing across all groups, a significant increase in OTUs identified as C aldenense (P = .004), C disporicum (P = .049), C lituseburense (P = .003), C tertium (P = .045), F plautii (P = .007), and T sanguinis (P = .033) was noted in the cohort of ASD children in whom abdominal pain had been reported. Comparisons solely between the 2 ASD groups, with and without abdominal pain, also showed 2 additional organisms of interest that were increased in the ASD pain group: P excrementihominis (P = .037) and T nexilis (P = .046). Plots depict the maximum and minimum (whiskers), upper and lower quartile limits (box), and median (horizontal line).
Figure 5
Figure 5
The identification of distinct microbial profiles of the NT-FGID, ASD-FGID, and ASD-FGID with abdominal pain groups was influenced greatly by the differences in relative abundances of the organisms listed (left). Several of these bacteria also were found to correlate with the serotonin pathway (center), as well as with multiple cytokines (right).

References

    1. Buie T., Campbell D.B., Fuchs G.J., 3rd Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1–S18.
    1. McElhanon B.O., McCracken C., Karpen S. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics. 2014;133:872–883.
    1. Gorrindo P., Williams K.C., Lee E.B. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res. 2012;5:101–108.
    1. Horvath K., Papadimitriou J.C., Rabsztyn A. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135:559–563.
    1. Fulceri F., Morelli M., Santocchi E. Gastrointestinal symptoms and behavioral problems in preschoolers with autism spectrum disorder. Dig Liver Dis. 2016;48:248–254.
    1. Furuta G.T., Williams K., Kooros K. Management of constipation in children and adolescents with autism spectrum disorders. Pediatrics. 2012;130(Suppl 2):S98–S105.
    1. Hyman P.E., Milla P.J., Benninga M.A. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006;130:1519–1526.
    1. Mayer E.A., Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381–396.
    1. Mayer E.A., Savidge T., Shulman R.J. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology. 2014;146:1500–1512.
    1. Levy R.L., Olden K.W., Naliboff B.D. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology. 2006;130:1447–1458.
    1. Daly E., Ecker C., Hallahan B. Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion. Brain. 2014;137:2600–2610.
    1. Croonenberghs J., Wauters A., Devreese K. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med. 2002;32:1457–1463.
    1. Croonenberghs J., Bosmans E., Deboutte D. Activation of the inflammatory response system in autism. Neuropsychobiology. 2002;45:1–6.
    1. Jyonouchi H., Sun S., Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001;120:170–179.
    1. Jyonouchi H., Geng L., Streck D.L. Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J Neuroinflammation. 2012;9:4.
    1. Li X., Chauhan A., Sheikh A.M. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207:111–116.
    1. Chez M.G., Dowling T., Patel P.B. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007;36:361–365.
    1. Croen L.A., Grether J.K., Yoshida C.K. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68:1104–1112.
    1. Kane M.J., Angoa-Perez M., Briggs D.I. Mice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to autism. PLoS One. 2012;7:e48975.
    1. Anderson G., Maes M. Redox regulation and the autistic spectrum: role of tryptophan catabolites, immuno-inflammation, autoimmunity and the amygdala. Curr Neuropharmacol. 2014;12:148–167.
    1. O'Mahony S.M., Clarke G., Borre Y.E. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32–48.
    1. Finegold S.M., Dowd S.E., Gontcharova V. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16:444–453.
    1. Williams B.L., Hornig M., Buie T. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One. 2011;6:e24585.
    1. Gondalia S.V., Palombo E.A., Knowles S.R. Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. Autism Res. 2012;5:419–427.
    1. Kang D.W., Park J.G., Ilhan Z.E. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One. 2013;8:e68322.
    1. De Angelis M., Piccolo M., Vannini L. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013;8:e76993.
    1. Wang L., Christophersen C.T., Sorich M.J. Increased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorder. Mol Autism. 2013;4:42.
    1. Wang W., Chen L., Zhou R. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014;52:398–406.
    1. Li G., Yang M., Zhou K. Diversity of duodenal and rectal microbiota in biopsy tissues and luminal contents in healthy volunteers. J Microbiol Biotechnol. 2015;25:1136–1145.
    1. Reigstad C.S., Salmonson C.E., Rainey J.F., 3rd Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29:1395–13403.
    1. Yano J.M., Yu K., Donaldson G.P. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264–276.
    1. Atarashi K., Tanoue T., Ando M. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163:367–380.
    1. Ohnmacht C., Park J.H., Cording S. Mucosal immunology. The microbiota regulates type 2 immunity through RORgammat(+) T cells. Science. 2015;349:989–993.
    1. Williams B.L., Hornig M., Parekh T. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio. 2012;3 e00261–11.
    1. Choi G.B., Yim Y.S., Wong H. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351:933–939.
    1. Barbara G., Stanghellini V., De Giorgio R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.
    1. Barbara G., Wang B., Stanghellini V. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.
    1. Hildebrand F., Tadeo R., Voigt A.Y. LotuS: an efficient and user-friendly OTU processing pipeline. Microbiome. 2014;2:30.
    1. Edgar R.C. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996–998.
    1. Ritari J., Salojarvi J., Lahti L. Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database. BMC Genomics. 2015;16:1056.
    1. Quast C., Pruesse E., Yilmaz P. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41:D590–D596.
    1. Anderson G.M., Feibel F.C., Cohen D.J. Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma and plasma ultrafiltrate. Life Sci. 1987;40:1063–1070.
    1. Parks D.H., Tyson G.W., Hugenholtz P. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics. 2014;30:3123–3124.
    1. Boccuto L., Chen C.F., Pittman A.R. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013;4:16.
    1. Muller C.L., Anacker A.M., Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience. 2016;321:24–41.
    1. Masi A., Quintana D.S., Glozier N. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2015;20:440–446.
    1. Gabriele S., Sacco R., Persico A.M. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014;24:919–929.
    1. Finegold S.M., Molitoris D., Song Y. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 2002;35:S6–S16.
    1. Song Y., Liu C., Finegold S.M. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459–6465.
    1. Parracho H.M., Bingham M.O., Gibson G.R. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54:987–991.
    1. Son J.S., Zheng L.J., Rowehl L.M. Comparison of fecal microbiota in children with autism spectrum disorders and neurotypical siblings in the Simons simplex collection. PLoS One. 2015;10:e0137725.
    1. Raymond F., Ouameur A.A., Deraspe M. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 2016;10:707–720.
    1. Cook E.H., Leventhal B.L. The serotonin system in autism. Curr Opin Pediatr. 1996;8:348–354.
    1. Saulnier D.M., Riehle K., Mistretta T.A. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141:1782–1791.
    1. Chumpitazi B.P., Cope J.L., Hollister E.B. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42:418–427.
    1. Ashwood P., Krakowiak P., Hertz-Picciotto I. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol. 2011;232:196–199.
    1. Ashwood P., Krakowiak P., Hertz-Picciotto I. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011;25:40–45.
    1. Hsiao E.Y., McBride S.W., Chow J. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci U S A. 2012;109:12776–12781.
    1. Wu W.L., Adams C.E., Stevens K.E. The interaction between maternal immune activation and alpha 7 nicotinic acetylcholine receptor in regulating behaviors in the offspring. Brain Behav Immun. 2015;46:192–202.
    1. Hsiao E.Y., Patterson P.H. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun. 2011;25:604–615.
    1. Singh V.K. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol. 1996;66:143–145.
    1. Pagan C., Delorme R., Callebert J. The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders. Transl Psychiatry. 2014;4:e479.
    1. Marler S., Ferguson B.J., Lee E.B. Brief report: whole blood serotonin levels and gastrointestinal symptoms in autism spectrum disorder. J Autism Dev Disord. 2016;46:1124–1130.
    1. Margolis K.G., Li Z., Stevanovic K. Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. J Clin Invest. 2016;126:2221–2235.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅